Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
HOUSTON, July 10, 2024 /PRNewswire/ --Moleculin Biotech, Inc, (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and …